Expand chart
Adapted from AARP; Chart: Axios Visuals

The cost of specialty drugs has skyrocketed over the last decade, with the cost of 61 widely used drugs almost tripling between 2006 and 2017, according to a new AARP report.

By the numbers: The average annual cost of a specialty drug in 2017 was almost $20,000 more than the median U.S. household income.

  • Specialty drugs are the most expensive class — and their prices are increasing rapidly, with annual increases ranging from 7% to 9.7% between 2012 and 2017.

The bottom line: The market is going to be increasingly driven by the use of specialty drugs, and that's going to be expensive.

Go deeper: The drug pricing maze

Go deeper

Erica Pandey, author of @Work
36 mins ago - Economy & Business

The dangerous instability of school re-openings

Illustration: Eniola Odetunde/Axios

Schools across the country have flip-flopped between in-person and remote learning — and that instability is taking a toll on students' ability to learn and their mental health.

The big picture: While companies were able to set long timelines for their return, schools — under immense political and social strain — had to rush to figure out how to reopen. The cobbled-together approach has hurt students, parents and teachers alike.

Dan Primack, author of Pro Rata
47 mins ago - Politics & Policy

Trump doesn't have a second-term economic plan

Illustration: Aïda Amer/Axios

President Trump has not laid out an economic agenda for his second term, despite the election being just eight days away.

Why it matters: This is unprecedented in modern presidential campaigns, and makes it harder for undecided voters to make an informed choice.

Amy Harder, author of Generate
1 hour ago - Energy & Environment
Column / Harder Line

How Trump’s energy endgame could go

Illustration: Aïda Amer/Axios

Expect President Trump to redouble his efforts loosening regulations and questioning climate-change science should he win reelection next month.

Driving the news: A second Trump administration would supercharge efforts by certain states, countries and companies to address global warming. But some wildcards could have a greener tinge.